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Abstract
We present a case of haemolytic uraemic syndrome (HUS) triggered by Shigella flexneri. Of the
Shigella species, only S. dysenteriae type 1 is said to produce Shiga toxin and consequently cause
HUS. Investigation of the complement system in this patient revealed a CD46 mutation. In
individuals with mutations in complement genes incomplete penetrance of atypical HUS (aHUS) is
seen, suggesting that a trigger, such as infection, is required for disease to manifest. In an era of
complement modulatory therapy for aHUS it is important to be alert to unusual presentations of
diarrhoeal-associated disease.
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Introduction
Haemolytic uraemic syndrome (HUS) is characterized by
the clinical triad of microangiopathic haemolytic anaemia,
thrombocytopenia and acute kidney injury (AKI). The
typical form is more common and is caused by enteric in-
fection with Shiga-toxin (Stx)-producing bacteria [1]. The
most frequent pathogens responsible are Stx-producing
Escherichia coli, particularly serotype O157:H7 (more recently
O104:H4 [2]) and Shigella dysenteriae type 1 [1].
The non-shiga-toxin-associated form of HUS or atypical
HUS (aHUS) is, in the majority of individuals, associated
with inherited and/or acquired defects in the complement
system resulting in complement over-activation [3]. In-
creased understanding of the pathogenesis of disease has
led to the successful introduction of the complement
inhibitor eculizumab in the treatment of aHUS [4].
Although there are anecdotal reports of eculizumab use
in Stx-associated HUS [5], the lack of evidence from a con-
trolled trial leaves clinicians uncertain as to its efficacy
and therefore it is not routinely used in Stx-HUS.
We report a case of HUS associated with Shigella flexneri
diarrhoea where subsequent investigation revealed a CD46
mutation.
Case report
A 38-year-old woman was referred by her primary care
physician following return from a visit to Holland where
she had experienced an episode of AKI. She had attended
the emergency department with a 2-day history of watery
diarrhoea and vomiting.
She was found to have AKI with a serum creatinine of
663 μmol/L. Admission haemoglobin was 10.9 g/dL, and
platelet count was 113 × 109/L with schistocytes on blood
film. The serum lactate dehydrogenase (LDH) was raised
at 1346 u/L and coagulation profile was normal.
Her past medical history consisted of severe asthma
with long-term steroid use. Her renal function was normal
with a creatinine of 90 μmol/L 2 months previously.
Following volume resuscitation her renal function did not
improve and the microangiopathic haemolytic anaemia
worsened. She did not have neurological or any other extra-
renal manifestations. Treatment with high-dose intravenous
steroids and therapeutic plasma exchange was initiated,
and she received twice-daily exchanges for a total of
10 days.
Shigella flexneri was isolated in both blood and stool
cultures. Intravenous piperacillin-tazobactam was adminis-
tered and a putative diagnosis of Stx-HUS was made. Blood
samples taken prior to the commencement of therapeutic
plasma exchange demonstrated that ADAMTS13 activity
was 78% of normal and C3 [1.25 g/L (0.68–1.38)] and C4
[0.24 g/L (0.18–0.60)] levels were normal. Polymerase chain
reaction (PCR) analyses for Stx1, Stx2 and STEC were nega-
tive. Serum creatinine peaked at 744 μmol/L and she did
not require renal replacement therapy. When she was dis-
charged 21 days after admission her serum creatinine was
140 μmol/L.
The patient was reviewed 17 days following discharge
with a serum creatinine of 85 μmol/L, a urine protein:crea-
tinine ratio of 32 mg/mmol, and a normal platelet count
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and LDH. Although there was no family history of renal
disease, because S. flexneri does not usually cause Stx-
HUS and the PCR for Stx had been negative, we investi-
gated for aHUS.
Convalescent concentrations of complement com-
ponents were C3 1.09 g/L (0.68–1.80), C4 0.17 g/L (018–
0.60), factor H 0.73 g/L (0.35–0.59) and factor I 63 mg/L
(38–58). Mutation screening of CFH, CFI, CD46, C3 and CFB
revealed a heterozygous CD46 splice site mutation (IVS2+
2T>G). This change has previously been identified in a
patient with aHUS and demonstrated to result in abnor-
mal splicing [6, 7]. FACS analysis of granulocytes from the
patient demonstrated that cell surface expression of CD46
was reduced by 50% (Figure 1). In the following year she
has had no further episodes of HUS, her serum creatinine is
88 μmol/L and urine protein:creatinine ratio is 6 mg/mmol.
Discussion
This patient presented with diarrhoea and had clinical
findings consistent with a renal thrombotic microangiopa-
thy (not biopsy proven). A presumptive diagnosis of
Stx-HUS secondary to S. flexneri infection was made
and her renal function fully recovered. However, it is unex-
pected for S. flexneri infection to cause Stx-HUS. Of the
Shigella species, only S. dysenteriae type 1 is said to
produce the Shiga toxin responsible for HUS [8]. Although
S. dysenteriae type 1 is the predominant cause of Shigella-
associated HUS, a few cases of S. flexneri HUS have been
reported [9]. The pathogenesis of non-S. dysenteriae-
associated HUS is unclear. Recent studies have failed to
detect shiga toxin sequences in non-S. dysenteriae type 1
[10] although historical reports suggest infrequent Stx-
producing strains [11]. In this case the Stx-PCR was nega-
tive and we therefore re-evaluated the diagnosis and in
particular investigated for atypical HUS.
Studies of familial aHUS have shown that not all individ-
uals carrying a mutation in a complement gene will
develop aHUS. It is now established that other factors, in-
cluding a trigger, are often needed for aHUS to manifest
[3]. In this patient we identified a functionally significant
mutation (IVS2+2T>G) in the gene encoding the trans-
membrane complement regulator CD46. We presume that
the S. flexneri diarrhoeal illness triggered aHUS in this
patient. A preceding non-E. coli O157 diarrhoeal illness
has been reported in 28% of patients with aHUS [12].
Escherichia coli O157 infections have also triggered the first
presentation of aHUS in a patient with a CD46 mutation
[13]. Another report described two patients with Stx-HUS
resulting in end-stage renal disease (ESRD) who developed
recurrent HUS following renal transplantation and were
subsequently found to have complement gene mutations
(CFI; p.V412M,MCP IVS2+2 T>G) [14].
The prognosis in individuals with aHUS associated with
only a CD46 mutation is good (0–6% risk of ESRD or death
within 1 year of the first episode [12]). In keeping with
this, our patient recovered normal renal function. In those
individuals with a CD46 mutation, who do progress to
ESRD, the outcome following transplantation is better
than patients with a mutation in CFH, CFI, C3 and CFB [15].
This is because the renal allograft will usually correct the
recipient’s membrane-bound CD46 defect, whereas there
is a high rate of recurrent disease post transplant in those
individuals with serum complement protein defects.
This case highlights the importance of screening for
underlying complement abnormalities in unusual presenta-
tions of diarrhoea-associated HUS. Making a diagnosis of
aHUS in this patient is important because of the impli-
cations for her future management and for her relatives.
She remains at risk (70–90% [12]) of recurrent episodes trig-
gered by infection and so she has been advised to present
whenever she is unwell so that appropriate investigations
can be performed. In the event of a recurrence, therapeutic
Fig. 1. Flow cytometry analysis of CD46 expression on lymphocytes in a normal subject (a) and the patient (b) measured on the same day. FACS analysis
was performed on the day of venepuncture. Mean fluorescence intensity for the patient was 1651 and 3658 for the control subject, consistent with
haploinsufficiency of CD46.
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plasma exchange would not be expected to be beneficial
because CD46 is cell surface bound and not a circulating
protein [12, 15]. However, she would be a candidate for
treatment with the complement inhibitor eculizumab,
which is a monoclonal antibody directed against C5 [16]. In
addition, her relatives have been counselled to present for
assessment should they become unwell, although they
have currently declined genetic screening.
Screening for underlying complement mutations is es-
sential if an aHUS patient has progressed to ESRD and re-
quires renal transplantation. This allows an individualized
approach to the use of eculizumab to prevent the morbid-
ity and mortality associated with recurrent aHUS in the
graft [17].
In conclusion, HUS presenting in the context of a
diarrhoeal infection should not be presumed to be Stx-
associated. Non-Stx diarrhoea commonly triggers aHUS in
individuals with underlying complement defects. Such
patients may benefit from complement modulatory therapy.
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